PDF

Fennec Pharmaceuticals Inc. Class Action Lawsuit

43 days left to seek lead plaintiff status

Case Summary

Company Name
Fennec Pharmaceuticals Inc.
Stock Symbol
FENC
Class Period
February 11, 2020 to August 10, 2020
Motion Deadline
November 2, 2020
Court
Middle District of North Carolina

The Fennec Pharmaceuticals Inc. class action lawsuit charges Fennec Pharmaceuticals, its CEO Rostislav Raykov and CFO Robert Andrade with violations of the Securities Exchange Act of 1934 and seeks to represent purchasers of Fennec Pharmaceuticals securities between February 11, 2020 and August 10, 2020, inclusive (the “Class Period”).  The Fennec Pharmaceuticals class action lawsuit was commenced on September 3, 2020 in the Middle District of North Carolina and is captioned Chapman v. Fennec Pharmaceuticals Inc., No. 20-cv-00812.

Fennec Pharmaceuticals is a biopharmaceutical company focused on the development of PEDMARK, a sodium thiosulfate anhydrous injection for the prevention of hearing loss associated with certain chemotherapy treatments in pediatric cancer patients.

The Fennec Pharmaceuticals class action lawsuit alleges that during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the manufacturing facilities for PEDMARK, Fennec Pharmaceuticals’ sole product candidate, did not comply with current good manufacturing practices; (2) as a result, regulatory approval for PEDMARK was reasonably likely to be delayed; and (3) as a result of the foregoing, defendants’ positive statements about Fennec Pharmaceuticals’ business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On August 11, 2020, Fennec Pharmaceuticals disclosed that it had received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding Fennec Pharmaceuticals’ New Drug Application for PEDMARK.  According to the CRL, “after recent completion of a pre-approval inspection of the manufacturing facility of [Fennec Pharmaceuticals’] drug product manufacturer, the FDA identified deficiencies resulting in a Form 483, which is a list of conditions or practices that are required to be resolved prior to the approval of PEDMARK.”  On this news, Fennec Pharmaceuticals’ share price fell more than 34%, damaging investors.

The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Fennec Pharmaceuticals securities during the Class Period to seek appointment as lead plaintiff in the Fennec Pharmaceuticals class action lawsuit.  A lead plaintiff will act on behalf of all other class members in directing the Fennec Pharmaceuticals class action lawsuit.  The lead plaintiff can select a law firm of its choice to litigate the Fennec Pharmaceuticals class action lawsuit.  An investor’s ability to share in any potential future recovery of the Fennec Pharmaceuticals class action lawsuit is not dependent upon serving as lead plaintiff.  If you wish to serve as lead plaintiff of the Fennec Pharmaceuticals class action lawsuit or have questions concerning your rights regarding the Fennec Pharmaceuticals class action lawsuit, please provide your information here or contact counsel, Michael Albert of Robbins Geller, at 800/449-4900 or 619/231-1058 or via e-mail at malbert@rgrdlaw.com.  Lead plaintiff motions for the Fennec Pharmaceuticals class action lawsuit must be filed with the court no later than November 2, 2020.

Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities class action litigation.  With 200 lawyers in 9 offices, Robbins Geller has obtained many of the largest securities class action recoveries in history.  For seven consecutive years, ISS Securities Class Action Services has ranked the Firm in its annual SCAS Top 50 Report as one of the top law firms in the world in both amount recovered for shareholders and total number of class action settlements.  Robbins Geller attorneys have helped shape the securities laws and have recovered tens of billions of dollars on behalf of aggrieved victims.  Beyond securing financial recoveries for defrauded investors, Robbins Geller also specializes in implementing corporate governance reforms, helping to improve the financial markets for investors worldwide.  Robbins Geller attorneys are consistently recognized by courts, professional organizations and the media as leading lawyers in the industry.

Class Period: February 11, 2020 - August 10, 2020
Main Menu